REG - IXICO plc - Trading Update

IXICOAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260421:nRSU2090Ba&default-theme=true

RNS Number : 2090B  IXICO plc  21 April 2026

IXICO PLC
 
("IXICO" or the "Company")

 

Half-year Trading update and Notice of Interim Results

 

Continued strong growth in first six months of trading in line with full-year
expectations

 

21 April 2026: IXICO plc (AIM: IXI), IXICO, a global leader in neuroscience
imaging and biomarker analytics, using its AI-driven platform to help advance
drug development in neurological disorders, today provides a trading update
ahead of its interim results for the six months ended 31 March 2026.

 

Key metrics:

 

·     Revenues expected to be up 23% to £3.9 million (H1 2025: £3.2m),
driven by new contract wins, contract extensions and an increased volume of
analyses in H12026 relative to the equivalent prior period.

 

·     Gross margin expected to increase to 53% (H1 2025: 50%).

 

·     Order book* expected to be £18.1 million; an increase of 38% on
31 March 2025 (H1 2025: £13.1m) and 31% on 30 September 2026 (FY 2025:
£13.8m).

 

·     Loss before interest, tax, depreciation and amortization expected
to be £0.5 million (H1 2025: £0.7m loss); reflecting increased revenues,
offset by full period impact of investments made in the Company's Innovate,
Lead, Scale strategy to deliver sustained revenue growth.

 

·     Cash position of £1.7 million (H1 2025: £5.0m).

 

·     The Group announced a capital raise of £10 million (£9.4 million
after placing costs) on 31 March 2026 to support the Group's Tech Bio strategy
to partner its IXI(TM) platform within the wider infrastructure of CROs, CTMS
and, ultimately, Clinical Healthcare providers.

 

*Order book refers to those client contracts that have been signed by the
Group but not yet delivered.

 

Notice of Results

 

The Company's first half results will be released on 19 May 2026.  Bram
Goorden (CEO) and Grant Nash (CFO) will provide a live presentation to all
existing and potential shareholders relating to the Interim Results and the
Company's progress and ongoing strategy via:

 

The Investor Meet Company platform on 19 May 2025 at 16:30 BST.

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
09:00 BST on 18 May 2026, or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet IXICO
PLC via:

 

https://www.investormeetcompany.com/ixico-plc/register-investor
(https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.investormeetcompany.com%2Fixico-plc%2Fregister-investor&data=05%7C02%7Cjames.chandler%40ixico.com%7Cfd7b2d98fdf74d5f362108dd8303c4d3%7Cd5a3b5c97a6b4ab9abee3de97e9d4955%7C0%7C0%7C638810774401694753%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=DoWkFpNoX3IapWeeYVz5qD7ikqrU%2Fms5pj7zJgFqfaM%3D&reserved=0)

 

Investors who already follow IXICO PLC on the Investor Meet Company platform
will automatically be invited.

 

A recording of the results presentation will be made available on the Group's
website.

 

Bram Goorden, CEO of IXICO, said: "The first half of the 2026 financial year
saw strong continued revenue growth driven by new contract wins and
extensions, and increased biomarker analysis activity.  This momentum,
combined with improved operational leverage, has delivered an increase in
gross margin while our order book has also grown significantly, providing good
visibility of future revenues.  While we continue to invest for growth, we
have reduced our EBITDA loss year-on-year, demonstrating progress towards
profitability. I am also very excited about the recently announced capital
raise which aims at deriving increased value from our IXI(TM) platform as a
premium technology."

 

 

 

 

 

Ends

 

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the UK version of the EU
Market Abuse Regulation 596/2014 which is part of UK law by virtue of the
European Union (Withdrawal) Act 2018, as amended and supplemented from time to
time. Upon the publication of this announcement, this inside information is
now considered to be in the public domain.

 

For further information please contact:

 

 IXICO plc                                        +44 (0) 20 3763 7499
 Grant Nash, Chief Financial Officer

 James Chandler, Chief Business Officer

 Cavendish Capital Markets Limited                +44 (0) 20 7220 0500

 (Nominated Adviser and Sole Broker)
 Giles Balleny, Isaac Hooper (Corporate Finance)

 Nigel Birks (Healthcare Specialist Sales)

 Harriet Ward (Corporate Broking)

 Michael F Johnson (Sales)

 

 

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is a global leader in neuroscience imaging and biomarker analytics,
using its proprietary AI-driven platform to help advance the treatment of
neurological disorders and reduce the uncertainties associated with drug
discovery, development and monitoring.   As a key part of the global
neurological disease research community, the Company has built a global
reputation and 20-year track record as an end-to-end Imaging Contract Research
Organisation (iCRO) working with leading pharma companies, innovative
biotechs, disease consortia and non-profit organisations. IXICO has supported
hundreds of neurological clinical trials, analysed hundreds of thousands of
scans and built an expansive network of expert imaging centres around the
world.

 

The IXI(TM) platform is tailor-made for neurological disease, reliably
processing data from global trials, precisely measuring key imaging biomarkers
associated with the identification, progression and treatment of diseases such
as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by
the platform and IXICO's expert scientists translating complex data into
clinically meaningful while minimizing data variability and increasing
reproducibility.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTSEAESSEMSEFL



            Copyright 2019 Regulatory News Service, all rights reserved